Intralesional PV-10 for the treatment of in-transit melanoma metastases-Results of a prospective, non-randomized, single center study.

J Surg Oncol · 2018 · PMC6668008 · PMID 29529343

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

trend toward significanceP = 0.07so close (0.05 < p ≤ 0.1)

There was a non‐significant trend toward significance for clinical benefit (CR + PR + SD), in younger patients treated with PV‐10 ( P = 0.07) although not for complete response ( P = 0.15).

also in 304 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.